We turn science into value
From where it is discovered, to where it is needed

Rooted in serious science.

ENTER

The story of Linnaea 林奈的故事

The name Linnaea comes from the north. From Sweden, from Linnaeus — the father of modern biological taxonomy, a man whose life's work was to give proper names and proper places to the forms of life that had not yet been carefully seen. Any serious biology, in one way or another, stands somewhere in his lineage.

The name also carries Karolinska in it: the medical school, the Nobel Prize in Physiology or Medicine, the Nordic tradition of medicine and natural history in which serious science was measured not by how loud it was, but by whether it lasted. It is a tradition we hold in high regard. It is also where the founder's own serious scientific training first began — a thread that quietly shaped how the company thinks about the work it chooses to do.

Linnaeus took one plant as his personal emblem: Linnaea borealis, the twinflower — a small, low subshrub of the northern forests, its stems creeping close to the ground, its roots reaching deep, its paired flowers blooming quietly, on schedule, through the boreal cold. Linnaeus described it as "lowly, insignificant, disregarded, flowering but for a brief space" — and then made it his own. Because the plant that goes unnoticed is often the one with the deepest roots. It is unshowy — but it flowers. It endures. And in its own quiet way, it gives.

This is what we take from the name, and what we intend to become. Our purpose is a plain one: to find scientific work of the highest order that has quietly waited, unnoticed, in the world's most serious laboratories — and to carry it, with care, to the physicians and patients for whom it was always meant. Not loud. Rooted. Patient about the timing, serious about the science, and honest about what we can and cannot yet say.

奈这个名字来自北方。来自瑞典,来自卡尔·林奈——现代生物分类学之父。他一生的工作,是为那些尚未被认真看待的生命,给予正式的命名与恰当的位置。今天所有严肃的生物学工作,都或多或少地站在他所开创的谱系里。

这个名字里也藏着卡罗林斯卡:那所医学院、那份诺贝尔生理学或医学奖、那种在北欧医学与博物学里流传下来的传统——衡量"严肃",不看声势,看能否长久。这是我们敬重的传统。它也是林奈生物创始人最早接受严肃科研训练的地方。这一份渊源,塑造了我们今天选择工作时的态度。

林奈为自己挑选了一株植物作为私人徽记:林奈花(Linnaea borealis)——北方森林里一种低矮的常绿小灌木。茎伏在地面上爬行,根扎得很深,成对的花在北方的严寒中安静地按时开放。林奈本人曾这样形容它——"低矮、微小、不被留意、花期短暂"——然后把它认作自己的徽记。那些不被留意的东西,往往根扎得最深。它不张扬,却按时开花,也能长久。以自己安静的方式,一年年地在做出贡献。

这就是我们从这个名字里承接的东西,也是我们想成为的样子。我们做的事其实朴素:去世界上最严肃的实验室里,找出那些水准很高、却还没有被真正推向临床的科学;然后认真地、稳稳地,把它带给那些本来就应该被它服务的医生和患者。不喧闹,扎根,愿意等,对科学严肃,对自己能说什么、还不能说什么,保持诚实。

03

Our focus today: urological diseases 我们目前的聚焦:泌尿系统疾病

We start where the gap between science and clinical value is at its widest. Urology is one of the clearest examples we know — a field of enormous patient populations, decades of accumulated science, and yet a striking scarcity of that science reaching the clinic. 我们选择从"科学与临床价值之间落差最大"的地方开始。泌尿系统疾病,是这类落差最清楚的领域之一——患者众多,几十年的科学积累也足够扎实,但真正被送到临床的,少之又少。

01 · The scale 01 · 规模

The scale is enormous. Chronic kidney disease alone affects an estimated 753 million people worldwide. Prostate cancer was diagnosed in over 1.5 million people in 2024, claiming nearly 420,000 lives. Benign prostatic hyperplasia affects approximately 94 million men. Add bladder cancer, overactive bladder, kidney stones, and interstitial cystitis, and the collective footprint of urological disease reaches well into the billions. 规模是巨大的。全球约有 7.53 亿人患慢性肾病;2024 年新发前列腺癌超过 150 万例,其中近 42 万人因此离世;良性前列腺增生影响约 9,400 万男性。再加上膀胱癌、膀胱过度活动症、肾结石、间质性膀胱炎——泌尿系统疾病合起来影响的,是十亿以上的人。

02 · Not a research gap 02 · 并非科学的缺席

This is not a field starved of science. In the United States alone, the National Institutes of Health invest hundreds of millions of dollars each year in urological research. More than fifteen thousand clinical trials in urology are actively registered on ClinicalTrials.gov. Tens of thousands of peer-reviewed papers are published in the field every year. The source science is there, and it is prolific. 这里从不缺科学。仅美国国立卫生研究院,每年就在泌尿系统研究上投入数亿美元;ClinicalTrials.gov 上正在登记的相关临床试验超过一万五千项;每年发表的同行评议论文数以万计。源头研究充足,也活跃。

03 · The translation gap 03 · 转化的缺口

In 2024, the U.S. Food and Drug Administration approved 50 new molecular entities across all fields of medicine. Only two of them were for urological disease. In 2023, out of 55 approvals, four were. Year after year, roughly one in twenty of the world's new medicines is directed at the urological patient — a population that reaches into the billions. 2024 年,美国 FDA 在所有医学领域共批准 50 款新分子实体。其中只有 2 款用于泌尿系统疾病。2023 年 55 款获批中,只有 4 款。年复一年,全球每 20 款新药中,真正到达泌尿患者手里的,大约只有 1 款——而这群患者,是以十亿计的。

04 · Where we come in 04 · 我们的位置

The gap lies elsewhere. Between the abundance of source science and the reality of what physicians can offer their patients, most of the work never crosses. A truly new therapy that changes the first-line standard of care in urology arrives, on average, only a handful of times each decade. The science exists. What is missing is the careful, patient work of turning it into value. This is where we choose to work. 落差在别处。在充沛的源头科学,与医生能真正开给患者的方案之间,大多数工作从未走完这一段。真正能改变泌尿领域一线治疗标准的新疗法,平均每十年也只出现有限的几次。科学不缺,缺的是那份把它认真地、耐心地转化为价值的工作。这就是我们选择工作的地方。

REFERENCES 参考文献
GBD Chronic Kidney Disease Collaboration. Lancet, 2020 — Global, regional, and national burden of chronic kidney disease, 1990–2017.
International Agency for Research on Cancer (IARC), World Health Organization. Global Cancer Observatory (GLOBOCAN), 2024.
Awedew AF, et al. Lancet Healthy Longevity, 2022 — Global, regional, and national burden of benign prostatic hyperplasia (GBD 2019).
NIH RePORTER, annual funding categorizations for renal, urological, and reproductive research.
ClinicalTrials.gov, active trial count within urology / kidney / prostate / bladder condition filters.
U.S. Food and Drug Administration, Novel Drug Approvals for 2024 (50 approvals total; urological indications: Anktiva for bladder cancer, Orlynvah for uUTI).
U.S. Food and Drug Administration, Novel Drug Approvals for 2023 (55 approvals total; urological indications: Jesduvroq, Filspari, Posluma, Rivfloza).
04

Our conviction 我们的信念

We do not chase everything new. What we choose to do — and how we choose to do it — is guided by a small set of convictions we hold firmly. 我们不追每一件新事物。我们选择做什么、怎么做,都由一组我们坚定持守的信念决定。

01 · The science we choose 01 · 我们所选择的科学

Rigor over novelty. Depth over breadth. We seek out scientific programs that have withstood years of independent verification — not the loudest ideas of the moment. 我们看重严谨,甚于新颖;看重深度,甚于广度。我们寻找的,是那些已经被独立验证过很多年的科学项目——而不是当下最喧嚣的想法。

02 · The bridge we build 02 · 我们所搭建的桥梁

Between a strong scientific finding and a clinical tool that actually helps a patient lies a long, unglamorous bridge — one that has to be built with care. Building that bridge, well, is what we do. 在一项扎实的科学发现,与一件真正能帮到患者的临床工具之间,横着一座漫长、不炫目、必须认真搭建的桥梁。认真把这座桥建好,就是我们做的事。

03 · The standard we hold 03 · 我们所持守的标准

We hold ourselves to two things: whether the science stands up, and whether it eventually reaches the person it was meant for. The rest is secondary. 我们对自己只有两条要求:科学本身是否站得住,以及它最终是否抵达了它本来应该服务的那个人。其余都在其次。

What we do 我们做
  • Work with programs that have earned real scientific standing. 与那些已经真正建立起科学地位的项目合作。
  • Stay accountable through the full path to the patient. 对通向患者的整段路径持续负责到底。
  • Describe our progress only when it is worth describing. 只在真正值得讲的时候,才讲我们的进展。
What we do not 我们不做
  • Chase what is currently popular. 追当下的热门。
  • Substitute press releases for evidence. 用新闻稿代替真正的证据。
  • Promise timelines the science cannot support. 承诺科学本身还给不出的时间表。
05

How we work 我们如何工作

What we do is find source science that has already earned its standing, and take responsibility for the long path that turns it into something a patient can actually use — and then do the same, again, with the next one. 我们做的事,是找到那些已经真正建立起科学地位的源头工作,然后负起责任,把它一步一步转化成患者手里真正能用的东西——做完一个,再做下一个。

01
Source 寻源

We search worldwide for scientific programs protected by mature global patents, built on independent research that has already stood the test of time. 我们在全球范围里,寻找那些拥有成熟专利保护、又经得起时间检验的科学项目。

02
Validate 验证

We put the science through the local validation it needs — laboratory, real-world, and clinical — so that it stands up in the environment where it will be used. 我们让科学在需要它的地方经历应有的验证——实验室里、真实世界中、临床上——确保它在真正被使用的环境里也站得住。

03
Translate 转化

We build the regulatory pathway, the manufacturing chain, and the physician-facing form the science needs to become a real clinical tool. 我们打通监管路径,搭好生产链条,把科学打磨成医生真正能用的临床形态。

04
Deliver 抵达

We deliver it to the physicians and patients it was meant for. And then we return to Source — and begin again. 我们把它送到本来应该服务的医生与患者手里。然后回到"寻源",重新开始。

05

Our pipeline 我们的管线

We are currently advancing two programs in urological disease — one diagnostic, one therapeutic. Each is at a stage where the science has been validated and the path forward is clear. 我们目前在推进两个泌尿系统疾病领域的项目——一个诊断,一个治疗。每一个都已经走到科学得到验证、前路清楚的阶段。

Both programs are protected by intellectual property owned or licensed by Linnaea Bio. Additional programs are under evaluation. 两个项目所依赖的知识产权,均由林奈生物拥有或已经引进。更多候选项目还在评估中。

← Back to Pipeline ← 返回管线
Program 01 · Companion Diagnostic 项目 01 · 伴随诊断
UroDx-01
A blood test that answers whether the standard drug will work — before the patient starts taking it. 一次血检,在患者开药之前回答"这个药对他管不管用"
The disease 疾病

Benign prostatic hyperplasia (BPH) is one of the most common chronic conditions of aging men. It affects more than 94 million men worldwide, over 20 million in China alone. The standard first-line therapy — 5α-reductase inhibitors, in use for over thirty years — works for most patients. But not for all. 良性前列腺增生(BPH)是老年男性最常见的慢性病之一。全球超过 9,400 万男性正在患病,仅中国就超过 2,000 万。目前的一线标准治疗——5α-还原酶抑制剂,已经用了三十多年——对大多数患者有效,但对所有人并不有效。

The unmet need 未被满足的需求

For roughly one in three men, the drug's molecular target simply isn't there — the SRD5A2 enzyme is silenced in their prostate tissue through epigenetic modification. Today there is no way to tell in advance. These patients spend six to twelve months, sometimes longer, on ineffective therapy while symptoms progress toward surgery. 约三分之一的患者体内本来就没有这个药的分子靶点——他们前列腺里的 SRD5A2 酶因为表观遗传修饰被沉默了。而在今天,临床上没有任何方法能在开药之前把这些人识别出来。他们要在一份注定无效的治疗里度过六到十二个月,有时更长,眼看着疾病一步步走向手术。

Our solution 我们的解决方案

A single peripheral blood test that measures SRD5A2 promoter methylation and identifies, before treatment begins, which patients will respond and which will not. Non-invasive. Same-day turnaround. Deployable in any standard hospital molecular laboratory. Built on fifteen years of source science and validated by two clinical studies. 一次外周血检测,测量 SRD5A2 启动子的甲基化状态——在治疗开始之前,就能判断哪些患者会有反应、哪些不会。无创。当日出结果。任何一家医院的分子实验室都可以运行。建立在十五年的源头研究之上,并已在两项临床研究里得到验证。

Where we are today 当前进展
Established 已建立
Source science · Fifteen years of independent research 源头科学 · 十五年独立研究
Secured 已引进
Global patent · in-licensed by Linnaea Bio 全球专利 · 林奈生物已获授权
Underway · Readout 2029 进行中 · 2029 年读出
Phase IIb randomized clinical trial (multi-center) IIb 期多中心随机对照研究
Target · 2028 目标 · 2028
First real-world clinical deployment · China · LDT pathway 中国首例真实世界临床应用 · LDT 路径
← Back to Pipeline ← 返回管线
Program 02 · Therapeutic 项目 02 · 治疗药物
UroTx-01
A new pathway for overactive bladder — moving beyond three decades of the same two drug classes. 膀胱过度活动症的新通路——超越三十年来重复的同两类药物
The disease 疾病

Lower urinary tract symptoms (LUTS), including overactive bladder, affect roughly half of all adults over the age of forty. It is not life-threatening, but its symptoms — urinary urgency, frequency, nocturia, incontinence — are relentless, and over the years and decades they erode sleep, mobility, and independence. 下尿路症状(LUTS),包括膀胱过度活动症,影响着大约一半四十岁以上的人。它不致命,但症状——尿急、尿频、夜尿、尿失禁——一直都在。在数年、数十年间,慢慢磨掉一个人的睡眠、行动能力、以及独立生活的能力。

The unmet need 未被满足的需求

Two drug classes dominate today's treatment — and both carry meaningful limitations. Most patients discontinue the first within a year, largely due to tolerability. The second carries cardiovascular safety considerations. When drugs fail, invasive options remain — with their own burdens. For a condition this common, the field has been waiting for a genuinely new pharmacological mechanism for over two decades. 目前的治疗,以两大类药物为主。两类都各有相当的局限:多数患者在一年内停用其中一类,主要因为副作用受不了;另一类则伴随心血管方面的安全性顾虑。药物治疗如果失败,就只剩下侵入性的方案——每一种都有它自己的代价。对这样一个常见的疾病来说,这个领域已经等了超过二十年,都没有等到一种真正意义上的全新药理机制。

Our solution 我们的解决方案

We are developing a first-in-class oral small molecule that engages a novel receptor pathway to relax bladder smooth muscle. In preclinical models, our lead candidate has demonstrated nanomolar target potency, high oral bioavailability, and clear in vivo efficacy — while operating outside the two mechanisms that limit current therapies. 我们正在开发一款口服的小分子药物(first-in-class),作用在一条能促进膀胱平滑肌舒张的新受体通路上。在临床前模型里,我们的先导化合物表现出纳摩尔级的靶点效力、很高的口服生物利用度、以及清晰的体内药效——同时避开了限制现有疗法的那两条机制。

Where we are today 当前进展
Established 已建立
Target validation · novel receptor pathway 靶点验证 · 全新受体通路
Complete 已完成
Medicinal chemistry · lead candidate selected 药物化学 · 先导化合物已筛选完成
Demonstrated 已验证
In vivo efficacy · rodent model 体内药效 · 啮齿动物模型
Secured 已引进
PCT patent application filed PCT 专利申请已递交
Underway 进行中
IND-enabling studies · GLP toxicology · CMC scale-up IND 支持性研究 · GLP 毒理 · CMC 放大
Next milestone 下一个里程碑
Investigational New Drug (IND) filing IND 申报

Let's have a real conversation 让我们认真谈一谈

Who we hope to hear from 我们希望遇见的人
  • Researchers whose work has quietly reached the standing we look for, and who are ready to see it reach the patient. 已经在自己的领域里做出真正科学地位、也希望这份工作能被送到患者身边的研究者。
  • Institutions and technology transfer offices with programs that have matured beyond the laboratory. 手上有科学项目、已经走出实验室阶段的机构,以及它们的技术转移办公室。
  • Physicians and clinical investigators in urological disease who want to think about what a real translation looks like. 从事泌尿系统疾病的临床医生和研究者——愿意一起思考"什么才算一次真正的转化"的人。
  • Investors who understand that serious work takes serious time. 明白一份认真的工作,需要认真的时间,才能真正做成的投资人。

We prefer conversations that begin with the science and end with the patient. If either end matters to you, we would like to meet. 我们更愿意从科学谈起、以患者收尾的对话。如果这两端对你都重要,我们很希望能见到你。

Rooted in serious science. Quietly, on schedule, in flower. 根植于严肃的科学。安静地,按时开花。